Tobam Alnylam Pharmaceuticals, Inc. Transaction History

Tobam

$234 Million
Q1 2025

A detailed history of Tobam transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Tobam holds 3,366 shares of ALNY stock, worth $1.04 Million. This represents 0.39% of its overall portfolio holdings.

Number of Shares

3,366

Previous 11,784 71.44%

Holding current value

$1.04 Million

Previous $2.77 Million 67.22%

% of portfolio

0.39%

Previous 0.85%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 16, 2025	SELL	$233.07 - $290.7 $1.96 Million - $2.45 Million	-8,418 Reduced 71.44%	3,366 $909,000
Q4 2024 Jan 28, 2025	SELL	$232.27 - $300.43 $4.57 Million - $5.91 Million	-19,683 Reduced 62.55%	11,784 $2.77 Million
Q3 2024 Oct 09, 2024	BUY	$233.81 - $287.01 $405,894 - $498,249	1,736 Added 5.84%	31,467 $8.65 Million
Q2 2024 Jul 29, 2024	SELL	$143.31 - $247.0 $5.64 Million - $9.71 Million	-39,331 Reduced 56.95%	29,731 $7.23 Million
Q1 2024 May 02, 2024	SELL	$146.51 - $198.2 $3.22 Million - $4.36 Million	-21,979 Reduced 24.14%	69,062 $10.3 Million
Q4 2023 Jan 26, 2024	SELL	$151.41 - $196.57 $1.82 Million - $2.36 Million	-12,003 Reduced 11.65%	91,041 $17.4 Million
Q3 2023 Oct 31, 2023	SELL	$170.77 - $211.65 $953,579 - $1.18 Million	-5,584 Reduced 5.14%	103,044 $18.2 Million
Q2 2023 Jul 31, 2023	SELL	$185.01 - $212.05 $3.35 Million - $3.84 Million	-18,132 Reduced 14.3%	108,628 $20.6 Million
Q1 2023 May 03, 2023	BUY	$182.66 - $235.53 $1.96 Million - $2.52 Million	10,712 Added 9.23%	126,760 $25.4 Million
Q4 2022 Feb 02, 2023	BUY	$185.53 - $241.31 $2.82 Million - $3.66 Million	15,183 Added 15.05%	116,048 $27.6 Million
Q3 2022 Nov 02, 2022	SELL	$138.54 - $232.0 $11 Million - $18.4 Million	-79,236 Reduced 44.0%	100,865 $20.2 Million
Q2 2022 Aug 02, 2022	BUY	$120.42 - $169.29 $2.95 Million - $4.15 Million	24,516 Added 15.76%	180,101 $26.3 Million
Q1 2022 Apr 25, 2022	BUY	$127.18 - $173.91 $9.38 Million - $12.8 Million	73,732 Added 90.08%	155,585 $25.4 Million
Q4 2021 Feb 15, 2022	BUY	$159.56 - $209.29 $11.6 Million - $15.2 Million	72,659 Added 790.29%	81,853 $13.9 Million
Q3 2021 Nov 12, 2021	BUY	$169.75 - $207.73 $91,155 - $111,551	537 Added 6.2%	9,194 $1.74 Million
Q2 2021 Aug 11, 2021	SELL	$128.63 - $176.89 $3.83 Million - $5.26 Million	-29,764 Reduced 77.47%	8,657 $1.47 Million
Q1 2021 May 11, 2021	SELL	$126.83 - $175.69 $4.8 Million - $6.65 Million	-37,863 Reduced 49.63%	38,421 $5.43 Million
Q4 2020 Feb 03, 2021	BUY	$122.97 - $147.0 $629,975 - $753,081	5,123 Added 7.2%	76,284 $9.92 Million
Q3 2020 Nov 12, 2020	BUY	$121.19 - $165.49 $2.59 Million - $3.54 Million	21,412 Added 43.04%	71,161 $10.4 Million
Q2 2020 Aug 17, 2020	BUY	$104.21 - $156.44 $5.18 Million - $7.78 Million	49,749 New	49,749 $7.37 Million
Q3 2019 Nov 12, 2019	SELL	$70.9 - $87.82 $59,839 - $74,120	-844 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$65.86 - $92.79 $7.6 Million - $10.7 Million	-115,358 Reduced 99.27%	844 $61,000
Q1 2019 May 15, 2019	SELL	$72.76 - $93.45 $11.5 Million - $14.7 Million	-157,403 Reduced 57.53%	116,202 $10.9 Million
Q4 2018 Feb 11, 2019	BUY	$62.67 - $88.33 $1.81 Million - $2.55 Million	28,824 Added 11.78%	273,605 $19.9 Million
Q3 2018 Nov 08, 2018	SELL	$87.52 - $122.67 $3.76 Million - $5.27 Million	-42,933 Reduced 14.92%	244,781 $21.4 Million
Q2 2018 Aug 03, 2018	BUY	$88.31 - $107.8 $6.91 Million - $8.44 Million	78,265 Added 37.37%	287,714 $28.3 Million
Q1 2018 May 14, 2018	BUY	$115.92 - $148.54 $11.3 Million - $14.5 Million	97,895 Added 87.76%	209,449 $24.9 Million
Q4 2017 Feb 14, 2018	BUY	$114.49 - $139.98 $12.8 Million - $15.6 Million	111,554	111,554 $14.2 Million

Others Institutions Holding ALNY

# of Institutions

720

Shares Held

111M

Call Options Held

978K

Put Options Held

881K

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $38.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tobam, based on Form 13F filings with the SEC.

News

Stay updated on Tobam with notifications on news.

Account